Warfarin management in patients on continuous anticoagulation therapy undergoing total knee replacement

Journal of Bone and Joint Surgery - Series B

Volumn 93 B, Issue 11, 2011, Pages 1497-1502

  Chana, R ^a   Salmon, L ^a   Waller, A ^a   Pinczewski, L ^a  

^a North Sydney Orthopaedic and Sports Medicine Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MALE; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANGE OF MOTION; SEX DIFFERENCE; TOTAL KNEE REPLACEMENT; TRANSFUSION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; KNEE JOINT; LENGTH OF STAY; MALE; MIDDLE AGED; PERIOPERATIVE CARE; RANGE OF MOTION, ARTICULAR; WARFARIN;

EID: 81155144682     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.93B11.27255     Document Type: Article

References (45)

1. No authors listed. National Joint Registry for England and Wales. 7th Annual Report, 2010. http://www.njrcentre.org.uk/NjrCentre/LinkClick.aspx? fileticket= QkPI7kk6B2E%3d&tabid=86&mid=523 (date last accessed 27 July 2011).
2. Davidson D, Graves S, Tomkins A, et al. Australian Orthopaedic Association National Joint Replacement Registry. Annual Report, 2010. http:// www.dmac.adelaide.edu.au/aoanjrr/documents/aoanjrrreport-2010.pdf (date last accessed 27 July 2011).
3. No authors listed. Australian Bureau of Statistics. Australian Social Trends. Catalogue 4102.1, 1999. http://www.abs.gov.au/ausstats/abs@.nsf/ 2f762f95845417aeca25706c00834efa/ 63378ca41ac510aeca2570ec00114198!OpenDocument (date last accessed 27 July 2011).
4. Grant PJ, Brotman DJ, Jaffer AK. Perioperative anticoagulant management. Med Clin North Am 2009;93:1105-1121.
5. Rhodes DA, Severson EP, Hodrick JT, Dunn HK, Hofmann AA. Discontinuation of warfarin is unnecessary in total knee arthroplasty. Clin Orthop 2010;468:120-126.
6. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(Suppl):8-21.
7. Asnis PD, Gardner MJ, Ranawat A, et al. The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplasty 2007;22:213-218.
8. Baker RI, Coughlin PB, Gallus AS, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis Haemostasis. Med J Aust 2004;181:492-497. (Pubitemid 39534470)
9. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):299-339.
10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl):338-400.
11. Carter G, Goss AN, Lloyd J, Tocchetti R. Current concepts of the management of dental extractions for patients taking warfarin. Aust Dent J 2003;48:89-96. (Pubitemid 38011254)
12. Carter G, Goss A. Tranexamic acid mouthwash: a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. Int J Oral Maxillofac Surg 2003;32:504-507. (Pubitemid 38263350)
13. Carter G, Goss A, Lloyd J, Tocchetti R. Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. J Oral Maxillofac Surg 2003;61:1432-1435. (Pubitemid 37464515)
14. Carter G, Goss AN, Lloyd J, Tocchetti R. Local haemostasis with autologous fibrin glue following surgical enucleation of a large cystic lesion in a therapeutically anti-coagulated patient. Br J Oral Maxillofac Surg 2003;41:275-276. (Pubitemid 37184475)
15. Kamien M. Remove the tooth, but don't stop the warfarin. Aust Fam Physician 2006;35:233-235.
16. Woods R, Savage N. Managing dental patients receiving warfarin therapy. Australian Prescriber 2002;25:69.
17. Malden NJ. Warfarin and extractions. Br Dent J 2003;194:65.
18. Blacker DJ. Warfarin reversal: consensus guidelines on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2005;182:365.
19. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am DentAssoc 2000;131:77-81.
20. Poller L, Thomson J. Evidence for "rebound" hypercoagulability after stopping anticoagulants. Lancet 1964;2:62-64.
21. Harenberg J, Haas R, Zimmerman R. Plasma hypercoagulability after termination of oral anticoagulants. Thromb Res 1983;29:627-633. (Pubitemid 13080954)
22. Genewein U, Haeberli A, Straub P, Beer JH. Rebound after cessation of oral anti-coagulant therapy: the biochemical evidence. Br J Haematology 1996;92:479-485. (Pubitemid 26042945)
23. Palareti G, Legnani C. Warfarin withdrawal: pharmacokinetic- pharmocodynamic consideration. Clin Pharmacokinetics 1996;30:300-313.
24. McLemore EC, Harold KL, Cha SS, Johnson DJ, Fowl RJ. The safety of open inguinal herniorraphy in patients on chronic warfarin therapy. Am J Surg 2006;192:860-864. (Pubitemid 44854833)
25. Anderson DR, Wilson SJ, Blundell J, et al. Comparison of a nomogram and physician adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty. J Bone Joint Surg [Am] 2002;84-A:1992-1997. (Pubitemid 35283364)
26. Leiberman JR, Wollaeger J, Dorey F, et al. The efficacy of prophylaxis with low dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg [Am] 1997;79-A:319-325. (Pubitemid 27136639)
27. Pelligrini V, Donaldson C, Farber D. The Mark Coventry Award: Prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop 2006;452:21-27. (Pubitemid 44690637)
28. Larson BJ, Zumberg MS, Kitchens CS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest 2005;127:922-927. (Pubitemid 40775525)
29. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002;22:83-96. (Pubitemid 34225974)
30. No authors listed. Anticoagulants and protamine. In: Martin J, ed. British national formulary. Sixtieth ed. London: Pharmaceutical Press, 2010:141-144.
31. Johanson NA, Lachiewicz PF, Lieberman JR, et al. AAOS Clinical Practice Guideline Summary. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty, 2009. http://www5.aaos.org/dvt/ physician/ ADU013/suppPDFs/OKO-ADU013-S10.pdf (date last accessed 27 July 2011).
32. Bong M, Patel V, Chang E, et al. Risks associated with blood transfusion after total knee arthroplasty. J Arthroplasty 2004;19:281-287. (Pubitemid 38519818)
33. Keating EM, Meding JB, Faris PM, Ritter MA. Predictors of transfusion risk in elective knee surgery. Clin Orthop 1998;357:50-59. (Pubitemid 29022432)
34. Larocque BJ, Gilbert K, Brien WF. A point score system for predicting the likelihood of blood transfusion after hip or knee arthroplasty. Transfusion 1997;37:463-467. (Pubitemid 27203933)
35. Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg [Am] 2002;84-A:216-220.
36. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136. (Pubitemid 27058587)
37. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164:66-70. (Pubitemid 38067390)
38. Weiss P, Soff GA, Halkin H, Seligsohn U. Decline in proteins C and S and factors II, VII and X during the initiation of warfarin therapy. Thromb Res 1987;45:783-790. (Pubitemid 17053699)
39. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511.
40. No authors listed. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism: Research Committee of the British Thoracic Society. Lancet 1992;340:873-876.
41. Sallah S, Thomas DP, Roberts HR. Warfarin and heparin-induced skin necrosis and the purple toe syndrome: infrequent complications of anticoagulant treatment. Thromb Haemost 1997;78:785-790. (Pubitemid 27365571)
42. Brinker MR, Reuben JD, Mull JR, et al. Comparison of general and epidural anaesthesia in patients undergoing primary unilateral THR. Orthopedics 1997;20:109-115. (Pubitemid 27091843)
43. Manolio TA, Beattie C, Christopherson R, Pearson TA. Regional versus general anesthesia in high-risk surgical patients: the need for a clinical trial. J Clin Anesth 1989;1:414-421.
44. Parker MJ, Urwin SC, Handoll HH, Griffiths R. General versus spinal/epidural anaesthesia for surgery for hip fractures in adults. Cochrane Database Syst Rev 2000;2:CD000521.
45. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):454-545.